# CD209L (L-SIGN) is a receptor for severe acute respirato

Proceedings of the National Academy of Sciences of the Unite
101, 15748-15753
DOI: 10.1073/pnas.0403812101

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochemical Journal, 2005, 392, 135-143. | 1.7 | 134 |
| 2 | Pathogenesis of severe acute respiratory syndrome. Current Opinion in Immunology, 2005, 17, 404-410. | 2.4 | 143 |
| 3 | Levels of complexity in pathogen recognition by C-type lectins. Current Opinion in Immunology, 2005, 17, 345-351. | 2.4 | 72 |
| 4 | The severe acute respiratory syndrome (SARS). Journal of NeuroVirology, 2005, 11, 455-468. | 1.0 | 13 |
| 5 | Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clinical Endocrinology, 2005, 63, 197-202. | 1.2 | 228 |
| 6 | A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirusâ€"induced lung injury. Nature Medicine, 2005, 11, 875-879. | 15.2 | 2,986 |
| 7 | Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO Journal, 2005, 24, 1634-1643. | 3.5 | 892 |
| 8 | Coronaviral hypothetical and structural proteins were found in the intestinal surface enterocytes and pneumocytes of severe acute respiratory syndrome (SARS). Modern Pathology, 2005, 18, 1432-1439. | 2.9 | 55 |
| 9 | Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Research, 2005, 66, 81-97. | 1.9 | 62 |
| 10 | From genome to antivirals: SARS as a test tube. Drug Discovery Today, 2005, 10, 345-352. | 3.2 | 16 |
| 11 | Structural Basis of Severe Acute Respiratory Syndrome Coronavirus ADP-Ribose-1â€³-Phosphate Dephosphorylation by a Conserved Domain of nsP3. Structure, 2005, 13, 1665-1675. | 1.6 | 175 |
| 12 | Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology, 2005, 334, 160-165. | 1.1 | 104 |
| 13 | Cells of human aminopeptidase N (CD13) transgenic mice are infected by human coronavirus-229E in vitro, but not in vivo. Virology, 2005, 335, 185-197. | 1.1 | 35 |
| 14 | Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology, 2005, 340, 174-182. | 1.1 | 149 |
| 15 | LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology, 2005, 340, 224-236. | 1.1 | 192 |
| 16 | Identification of an alternative 5â€²-untranslated exon and new polymorphisms of angiotensin-converting enzyme 2 gene: Lack of association with SARS in the Vietnamese population. American Journal of Medical Genetics, Part A, 2005, 136A, 52-57. | 0.7 | 49 |
| 17 | Recurrent mutations associated with isolation and passage of SARS coronavirus in cells from non-human primates. Journal of Medical Virology, 2005, 76, 435-440. | 2.5 | 27 |
| 18 | SARS Vaccine Development. Emerging Infectious Diseases, 2005, 11, 1016-1020. | 2.0 | 145 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Identification of Two Critical Amino Acid Residues of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Its Variation in Zoonotic Tropism Transition via a Double Substitution Strategy. Journal of Biological Chemistry, 2005, 280, 29588-29595. | 1.6 | 152 |
| 20 | Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases. PLoS Biology, 2005, 3, e324. | 2.6 | 547 |
| 21 | SARS: Understanding the Virus and Development of Rational Therapy. Current Molecular Medicine, 2005, 5, 677-697. | 0.6 | 23 |
| 22 | Exogenous ACE2 Expression Allows Refractory Cell Lines To Support Severe Acute Respiratory Syndrome Coronavirus Replication. Journal of Virology, 2005, 79, 3846-3850. | 1.5 | 143 |
| 23 | ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. Journal of Virology, 2005, 79, 14614-14621. | 1.5 | 782 |
| 24 | Interactions Between Virus Proteins and Host Cell Membranes During the Viral Life Cycle. International Review of Cytology, 2005, 245, 171-244. | 6.2 | 50 |
| 25 | Humanized mice develop coronavirus respiratory disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8073-8074. | 3.3 | 9 |
| 26 | Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive Infection. Journal of Immunology, 2005, 174, 7977-7985. | 0.4 | 141 |
| 27 | Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and Immunogenicity of a Major Neutralizing Domain. Journal of Virology, 2005, 79, 11638-11646. | 1.5 | 55 |
| 28 | Apical Entry and Release of Severe Acute Respiratory Syndrome-Associated Coronavirus in Polarized Calu-3 Lung Epithelial Cells. Journal of Virology, 2005, 79, 9470-9479. | 1.5 | 124 |
| 29 | Comparative Host Gene Transcription by Microarray Analysis Early after Infection of the Huh7 Cell Line by Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus 229E. Journal of Virology, 2005, 79, 6180-6193. | 1.5 | 97 |
| 30 | Identification and Characterization of the Putative Fusion Peptide of the Severe Acute Respiratory Syndrome-Associated Coronavirus Spike Protein. Journal of Virology, 2005, 79, 7195-7206. | 1.5 | 126 |
| 31 | Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 797-801. | 3.3 | 252 |
| 32 | The Heritage of Pathogen Pressures and Ancient Demography in the Human Innate-Immunity CD209/CD209L Region. American Journal of Human Genetics, 2005, 77, 869-886. | 2.6 | 81 |
| 33 | Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14040-14045. | 3.3 | 1,322 |
| 34 | Assembly of Severe Acute Respiratory Syndrome Coronavirus RNA Packaging Signal into Virus-Like Particles Is Nucleocapsid Dependent. Journal of Virology, 2005, 79, 13848-13855. | 1.5 | 176 |
| 35 | Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus. Microbiology and Molecular Biology Reviews, 2005, 69, 635-664. | 2.9 | 951 |
| 36 | Role of the C-type lectins DC-SIGN and L-SIGN in Leishmania interaction with host phagocytes. Immunobiology, 2005, 210, 185-193. | 0.8 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Selection of and recombination between minor variants lead to the adaptation of an avian coronavirus to primate cells. Biochemical and Biophysical Research Communications, 2005, 336, 417-423. | 1.0 | 70 |
| 38 | Pneumonitis and Multi-Organ System Disease in Common Marmosets (Callithrix jacchus) Infected with the Severe Acute Respiratory Syndrome-Associated Coronavirus. American Journal of Pathology, 2005, 167, 455-463. | 1.9 | 101 |
| 39 | Molecular mechanisms of severe acute respiratory syndrome (SARS). Respiratory Research, 2005, 6, 8. | 1.4 | 78 |
| 40 | The Molecular Biology of Coronaviruses. Advances in Virus Research, 2006, 66, 193-292. | 0.9 | 1,342 |
| 42 | Architecture of the SARS coronavirus prefusion spike. Nature Structural and Molecular Biology, 2006, 13, 751-752. | 3.6 | 239 |
| 43 | Mustela Vison ACE2 Functions as a Receptor for Sars-Coronavirus. Advances in Experimental Medicine and Biology, 2006, 581, 507-510. | 0.8 | 12 |
| 44 | Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. FEBS Letters, 2006, 580, 2414-2420. | 1.3 | 36 |
| 45 | Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus. Journal of Structural Biology, 2006, 155, 176-194. | 1.3 | 38 |
| 46 | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Research, 2006, 120, 146-155. | 1.1 | 66 |
| 47 | Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. PLoS Medicine, 2006, 3, e237. | 3.9 | 594 |
| 48 | SARS: clinical presentation, transmission, pathogenesis and treatment options. Clinical Science, 2006, 110, 193-204. | 1.8 | 43 |
| 51 | Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). Perspectives in Medical Virology, 2006, 16, 43-95. | 0.1 | 20 |
| 52 | How the SARS coronavirus causes disease: host or organism?. Journal of Pathology, 2006, 208, 142-151. | 2.1 | 46 |
| 53 | Hosting the severe acute respiratory syndrome coronavirus: specific cell factors required for infection. Cellular Microbiology, 2006, 8, 1211-1218. | 1.1 | 19 |
| 54 | Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nature Genetics, 2006, 38, 38-46. | 9.4 | 127 |
| 55 | Modification of SARS-CoV S1 gene render expression in Pichia pastoris. Virus Genes, 2006, 33, 329-335. | 0.7 | 3 |
| 56 | Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. Journal of Molecular Medicine, 2006, 84, 814-820. | 1.7 | 120 |
| 57 | SARS coronavirus 7a protein blocks cell cycle progression at G0/G1 phase via the cyclin D3/pRb pathway. Virology, 2006, 346, 74-85. | 1.1 | 132 |

| # | Article | IF | Citations |
|---|---|---|---|
| 58 | Murine encephalitis caused by HCoV-OC43, a human coronavirus with broad species specificity, is partly immune-mediated. Virology, 2006, 347, 410-421. | 1.1 | 62 |
| 59 | Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology, 2006, 350, 15-25. | 1.1 | 181 |
| 60 | Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites in different epidemic groups. BMC Microbiology, 2006, 6, 88. | 1.3 | 54 |
| 61 | Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Medicinal Research Reviews, 2006, 26, 414-433. | 5.0 | 26 |
| 62 | Highly Conserved Regions within the Spike Proteins of Human Coronaviruses 229E and NL63 Determine Recognition of Their Respective Cellular Receptors. Journal of Virology, 2006, 80, 8639-8652. | 1.5 | 101 |
| 63 | Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses. Current Pharmaceutical Design, 2006, 12, 4573-4590. | 0.9 | 145 |
| 64 | The Location of Asparagine-linked Glycans on West Nile Virions Controls Their Interactions with CD209 (Dendritic Cell-specific ICAM-3 Grabbing Nonintegrin). Journal of Biological Chemistry, 2006, 281, 37183-37194. | 1.6 | 98 |
| 65 | Animal Origins of the Severe Acute Respiratory Syndrome Coronavirus: Insight from ACE2-S-Protein Interactions. Journal of Virology, 2006, 80, 4211-4219. | 1.5 | 247 |
| 66 | Extremely Low Exposure of a Community to Severe Acute Respiratory Syndrome Coronavirus: False Seropositivity due to Use of Bacterially Derived Antigens. Journal of Virology, 2006, 80, 8920-8928. | 1.5 | 15 |
| 67 | Internalizing Antibodies to the C-Type Lectins, L-SIGN and DC-SIGN, Inhibit Viral Glycoprotein Binding and Deliver Antigen to Human Dendritic Cells for the Induction of T Cell Responses. Journal of Immunology, 2006, 176, 426-440. | 0.4 | 51 |
| 68 | Emerging Respiratory Viruses: Challenges and Vaccine Strategies. Clinical Microbiology Reviews, 2006, 19, 614-636. | 5.7 | 134 |
| 69 | Important Role for the Transmembrane Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein during Entry. Journal of Virology, 2006, 80, 1302-1310. | 1.5 | 75 |
| 71 | Identifying Epitopes Responsible for Neutralizing Antibody and DC-SIGN Binding on the Spike Glycoprotein of the Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2006, 80, 10315-10324. | 1.5 | 45 |
| 72 | Preferential Infection of Mature Dendritic Cells by Mouse Hepatitis Virus Strain JHM. Journal of Virology, 2006, 80, 2506-2514. | 1.5 | 31 |
| 73 | All but the Shortest Polymorphic Forms of the Viral Receptor DC-SIGNR Assemble into Stable Homo- and Heterotetramers. Journal of Biological Chemistry, 2006, 281, 16794-16798. | 1.6 | 16 |
| 74 | Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion. Expert Review of Vaccines, 2006, 5, 371-380. | 2.0 | 1 |
| 75 | Significant Redox Insensitivity of the Functions of the SARS-CoV Spike Glycoprotein. Journal of Biological Chemistry, 2006, 281, 9200-9204. | 1.6 | 49 |
| 77 | Specific Asparagine-Linked Glycosylation Sites Are Critical for DC-SIGN- and L-SIGN-Mediated Severe Acute Respiratory Syndrome Coronavirus Entry. Journal of Virology, 2007, 81, 12029-12039. | 1.5 | 123 |

| # | Article | IF | Citations |
|---|---|---|---|
| 78 | Heparan Sulfate Is a Selective Attachment Factor for the Avian Coronavirus Infectious Bronchitis Virus Beaudette. Avian Diseases, 2007, 51, 45-51. | 0.4 | 69 |
| 79 | Cell Entry by Enveloped Viruses: Redox Considerations for HIV and SARS-Coronavirus. Antioxidants and Redox Signaling, 2007, 9, 1009-1034. | 2.5 | 84 |
| 81 | SARS-CoV accessory protein 7a directly interacts with human LFA-1. Biological Chemistry, 2007, 388, 1325-1332. | 1.2 | 24 |
| 82 | The C-type lectin L-SIGN differentially recognizes glycan antigens on egg glycosphingolipids and soluble egg glycoproteins from Schistosoma mansoni. Glycobiology, 2007, 17, 1104-1119. | 1.3 | 24 |
| 83 | Severe Acute Respiratory Syndrome Coronavirus Infection of Mice Transgenic for the Human Angiotensin-Converting Enzyme 2 Virus Receptor. Journal of Virology, 2007, 81, 1162-1173. | 1.5 | 222 |
| 84 | Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection. Clinical Microbiology Reviews, 2007, 20, 660-694. | 5.7 | 886 |
| 85 | The Cytoplasmic Tail of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains a Novel Endoplasmic Reticulum Retrieval Signal That Binds COPI and Promotes Interaction with Membrane Protein. Journal of Virology, 2007, 81, 2418-2428. | 1.5 | 168 |
| 86 | Association of ICAM3 Genetic Variant with Severe Acute Respiratory Syndrome. Journal of Infectious Diseases, 2007, 196, 271-280. | 1.9 | 33 |
| 87 | Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcÎ³RII-dependent entry into B cells in vitro. Vaccine, 2007, 25, 729-740. | 1.7 | 197 |
| 88 | Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine, 2007, 25, 6981-6991. | 1.7 | 61 |
| 89 | The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages. Immunobiology, 2007, 212, 201-211. | 0.8 | 107 |
| 90 | Molecular Pathology in the Lungs of Severe Acute Respiratory Syndrome Patients. American Journal of Pathology, 2007, 170, 538-545. | 1.9 | 74 |
| 91 | Pathology and Pathogenesis of Severe Acute Respiratory Syndrome. American Journal of Pathology, 2007, 170, 1136-1147. | 1.9 | 504 |
| 92 | The Immunobiology of SARS. Annual Review of Immunology, 2007, 25, 443-472. | 9.5 | 242 |
| 93 | Metabonomic Evaluation of Schaedler Altered Microflora Rats. Chemical Research in Toxicology, 2007, 20, 1388-1392. | 1.7 | 25 |
| 95 | Quantitative temporalâ€spatial distribution of severe acute respiratory syndromeâ€associated coronavirus (SARSâ€CoV) in postâ€mortem tissues. Journal of Medical Virology, 2007, 79, 1245-1253. | 2.5 | 36 |
| 96 | Molecular pathogenesis of severe acute respiratory syndrome. Microbes and Infection, 2007, 9, 119-126. | 1.0 | 11 |
| 97 | The emerging role of ACE2 in physiology and disease. Journal of Pathology, 2007, 212, 1-11. | 2.1 | 380 |

| # | Article | IF | Citations |
|---|---|---|---|
| 98 | Lack of support for an association between CLEC4M homozygosity and protection against SARS coronavirus infection. Nature Genetics, 2007, 39, 692-693. | 9.4 | 19 |
| 99 | Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. Virology, 2007, 362, 26-37. | 1.1 | 142 |
| 100 | Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS. Virology, 2007, 363, 288-302. | 1.1 | 17 |
| 101 | Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cellular and Molecular Life Sciences, 2007, 64, 2006-2012. | 2.4 | 124 |
| 102 | Structural proteomics of the SARS coronavirus: a model response to emerging infectious diseases. Journal of Structural and Functional Genomics, 2007, 8, 85-97. | 1.2 | 35 |
| 103 | DC-SIGN and L-SIGN: the SIGNs for infection. Journal of Molecular Medicine, 2008, 86, 861-874. | 1.7 | 127 |
| 104 | siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 709-715. | 1.3 | 23 |
| 105 | Structural and Dynamic Characterization of the Interaction of the Putative Fusion Peptide of the S2 SARS-CoV Virus Protein with Lipid Membranes. Journal of Physical Chemistry B, 2008, 112, 6997-7007. | 1.2 | 29 |
| 106 | Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Research, 2008, 133, 4-12. | 1.1 | 150 |
| 107 | SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. Virus Research, 2008, 133, 33-44. | 1.1 | 111 |
| 108 | Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochemical and Biophysical Research Communications, 2008, 369, 344-349. | 1.0 | 221 |
| 109 | Bench-to-bedside review: Rare and common viral infections in the intensive care unit â€“ linking pathophysiology to clinical presentation. Critical Care, 2008, 12, 219. | 2.5 | 17 |
| 110 | Persistent Replication of Severe Acute Respiratory Syndrome Coronavirus in Human Tubular Kidney Cells Selects for Adaptive Mutations in the Membrane Protein. Journal of Virology, 2008, 82, 5137-5144. | 1.5 | 50 |
| 111 | Mechanisms of Zoonotic Severe Acute Respiratory Syndrome Coronavirus Host Range Expansion in Human Airway Epithelium. Journal of Virology, 2008, 82, 2274-2285. | 1.5 | 107 |
| 112 | Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets. Veterinary Pathology, 2008, 45, 551-562. | 0.8 | 115 |
| 113 | Mechanisms of Severe Acute Respiratory Syndrome Pathogenesis and Innate Immunomodulation. Microbiology and Molecular Biology Reviews, 2008, 72, 672-685. | 2.9 | 95 |
| 114 | Utilization of DC-SIGN for Entry of Feline Coronaviruses into Host Cells. Journal of Virology, 2008, 82, 11992-11996. | 1.5 | 50 |
| 115 | Pathways of Cross-Species Transmission of Synthetically Reconstructed Zoonotic Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2008, 82, 8721-8732. | 1.5 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 116 | Amiodarone Alters Late Endosomes and Inhibits SARS Coronavirus Infection at a Post-Endosomal Level. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 142-149. | 1.4 | 91 |
| 117 | Clinical features, pathogenesis and immunobiology of severe acute respiratory syndrome. Current Opinion in Pulmonary Medicine, 2008, 14, 241-247. | 1.2 | 12 |
| 118 | Pathogenesis of severe acute respiratory syndrome. Chinese Medical Journal, 2008, 121, 1722-1731. | 0.9 | 3 |
| 119 | SARS vaccines: where are we?. Expert Review of Vaccines, 2009, 8, 887-898. | 2.0 | 165 |
| 120 | Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections. Infectious Disorders - Drug Targets, 2009, 9, 223-245. | 0.4 | 47 |
| 121 | Identification of Major Histocompatibility Complex Class I C Molecule as an Attachment Factor That Facilitates Coronavirus HKU1 Spike-Mediated Infection. Journal of Virology, 2009, 83, 1026-1035. | 1.5 | 35 |
| 122 | The spike protein of SARS-CoV â€" a target for vaccine and therapeutic development. Nature Reviews Microbiology, 2009, 7, 226-236. | 13.6 | 1,405 |
| 123 | Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein. Biochemical and Biophysical Research Communications, 2009, 390, 1056-1060. | 1.0 | 12 |
| 124 | Identification of a New Region of SARS-CoV S Protein Critical for Viral Entry. Journal of Molecular Biology, 2009, 394, 600-605. | 2.0 | 31 |
| 125 | Interaction of a peptide corresponding to the loop domain of the S2 SARS-CoV virus protein with model membranes. Molecular Membrane Biology, 2009, 26, 236-248. | 2.0 | 9 |
| 126 | Identification of four novel DC-SIGN ligands on Mycobacterium bovis BCG. Protein and Cell, 2010, 1, 859-870. | 4.8 | 48 |
| 127 | TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Research, 2010, 85, 551-555. | 1.9 | 117 |
| 128 | Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein. Virology, 2010, 399, 257-269. | 1.1 | 100 |
| 129 | Lectin-like interactions in virusâ€"cell recognition. , 2010, , 567-584. | | 1 |
| 130 | A Single Asparagine-Linked Glycosylation Site of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Facilitates Inhibition by Mannose-Binding Lectin through Multiple Mechanisms. Journal of Virology, 2010, 84, 8753-8764. | 1.5 | 127 |
| 131 | Upregulation of the Chemokine (C-C Motif) Ligand 2 via a Severe Acute Respiratory Syndrome Coronavirus Spike-ACE2 Signaling Pathway. Journal of Virology, 2010, 84, 7703-7712. | 1.5 | 110 |
| 132 | Feline Lectin Activity Is Critical for the Cellular Entry of Feline Infectious Peritonitis Virus. Journal of Virology, 2010, 84, 7917-7921. | 1.5 | 31 |
| 133 | The highly cited SARS research literature. Critical Reviews in Microbiology, 2010, 36, 299-317. | 2.7 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 134 | HIV-1 Transmission by Dendritic Cell-specific ICAM-3-grabbing Nonintegrin (DC-SIGN) Is Regulated by Determinants in the Carbohydrate Recognition Domain That Are Absent in Liver/Lymph Node-SIGN (L-SIGN). Journal of Biological Chemistry, 2010, 285, 2100-2112. | 1.6 | 22 |
| 135 | Severe Acute Respiratory Syndrome and Coronavirus. Infectious Disease Clinics of North America, 2010, 24, 619-638. | 1.9 | 57 |
| 136 | Identification of NCAM that interacts with the PHE-CoV spike protein. Virology Journal, 2010, 7, 254. | 1.4 | 22 |
| 137 | CD209 (DC-SIGN) â^'336A>G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese. Human Immunology, 2010, 71, 702-707. | 1.2 | 37 |
| 138 | Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission. Journal of Virology, 2010, 84, 3134-3146. | 1.5 | 595 |
| 139 | The cell biology of receptor-mediated virus entry. Journal of Cell Biology, 2011, 195, 1071-1082. | 2.3 | 425 |
| 140 | SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission. Current Opinion in Virology, 2011, 1, 624-634. | 2.6 | 149 |
| 141 | Role of DC-SIGN and L-SIGN receptors in HIV-1 vertical transmission. Human Immunology, 2011, 72, 305-311. | 1.2 | 31 |
| 142 | Genetic determinants of pathogenesis by feline infectious peritonitis virus. Veterinary Immunology and Immunopathology, 2011, 143, 265-268. | 0.5 | 19 |
| 143 | Intriguing interplay between feline infectious peritonitis virus and its receptors during entry in primary feline monocytes. Virus Research, 2011, 160, 32-39. | 1.1 | 23 |
| 144 | Different host cell proteases activate the SARS-coronavirus spike-protein for cellâ€"cell and virusâ€"cell fusion. Virology, 2011, 413, 265-274. | 1.1 | 114 |
| 145 | Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin. Antiviral Research, 2011, 90, 22-32. | 1.9 | 71 |
| 146 | Lectin Switching During Dengue Virus Infection. Journal of Infectious Diseases, 2011, 203, 1775-1783. | 1.9 | 58 |
| 147 | N-Linked Glycosylation Facilitates Sialic Acid-Independent Attachment and Entry of Influenza A Viruses into Cells Expressing DC-SIGN or L-SIGN. Journal of Virology, 2011, 85, 2990-3000. | 1.5 | 113 |
| 148 | Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcÎ³R Pathway. Journal of Virology, 2011, 85, 10582-10597. | 1.5 | 294 |
| 149 | Feline and Canine Coronaviruses: Common Genetic and Pathobiological Features. Advances in Virology, 2011, 2011, 1-11. | 0.5 | 56 |
| 150 | Recombinant Live Vaccines to Protect Against the Severe Acute Respiratory Syndrome Coronavirus. , 2011, , 73-97. | | 5 |
| 151 | Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein. Viruses, 2012, 4, 1011-1033. | 1.5 | 1,086 |

| # | Article | IF | Citations |
|---|---|---|---|
| 152 | Respiratory Syncytial Virus Glycoprotein G Interacts with DC-SIGN and L-SIGN To Activate ERK1 and ERK2. Journal of Virology, 2012, 86, 1339-1347. | 1.5 | 71 |
| 153 | Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerging Microbes and Infections, 2012, 1, 1-8. | 3.0 | 36 |
| 154 | Monitoring of S Protein Maturation in the Endoplasmic Reticulum by Calnexin Is Important for the Infectivity of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2012, 86, 11745-11753. | 1.5 | 63 |
| 155 | Virus entry: old viruses, new receptors. Current Opinion in Virology, 2012, 2, 4-13. | 2.6 | 28 |
| 156 | Characterization of cellular furin content as a potential factor determining the susceptibility of cultured human and animal cells to coronavirus infectious bronchitis virus infection. Virology, 2012, 433, 421-430. | 1.1 | 36 |
| 157 | Milk Derived Peptides with Immune Stimulating Antiviral Properties. , 0, , . | | 2 |
| 158 | Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Reviews in Medical Virology, 2012, 22, 2-17. | 3.9 | 82 |
| 159 | Expression of the C-type lectins DC-SIGN or L-SIGN alters host cell susceptibility for the avian coronavirus, infectious bronchitis virus. Veterinary Microbiology, 2012, 157, 285-293. | 0.8 | 30 |
| 160 | Interaction of L-SIGN with Hepatitis C Virus Envelope Protein E2 Up-Regulates Rafâ€“MEKâ€“ERK Pathway. Cell Biochemistry and Biophysics, 2013, 66, 589-597. | 0.9 | 5 |
| 161 | The replication of a mouse adapted SARS-CoV in a mouse cell line stably expressing the murine SARS-CoV receptor mACE2 efficiently induces the expression of proinflammatory cytokines. Journal of Virological Methods, 2013, 193, 639-646. | 1.0 | 15 |
| 162 | A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virology Journal, 2013, 10, 266. | 1.4 | 127 |
| 163 | Innate Immune Response of Human Alveolar Type II Cells Infected with Severe Acute Respiratory Syndromeâ€“Coronavirus. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 742-748. | 1.4 | 255 |
| 164 | Caveolar Endocytosis Is Required for Human PSGL-1-Mediated Enterovirus 71 Infection. Journal of Virology, 2013, 87, 9064-9076. | 1.5 | 41 |
| 165 | Correlating Cell Line Studies With Tissue Distribution of DPP4/TMPRSS2 and Human Biological Samples May Better Define the Viral Tropism of MERS-CoV. Journal of Infectious Diseases, 2013, 208, 1350-1351. | 1.9 | 9 |
| 166 | Role of DC-SIGN in Lassa Virus Entry into Human Dendritic Cells. Journal of Virology, 2013, 87, 11504-11515. | 1.5 | 67 |
| 167 | Pathogenesis of Human Coronaviruses Other than Severe Acute Respiratory Syndrome Coronavirus. , 0, , 313-324. | | 14 |
| 168 | Angiotensin-Converting Enzyme 2, the Cellular Receptor for Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63. , 0, , 147-156. | | 1 |
| 169 | The avian coronavirus spike protein. Virus Research, 2014, 194, 37-48. | 1.1 | 76 |

| # | Article | IF | Citations |
|---|---|---|---|
| 170 | <scp>NMR</scp> evidence for oligosaccharide release from the dendriticâ€cell specific intercellular adhesion moleculeÂ3â€grabbing nonâ€integrinâ€related (<scp>CLEC</scp>4M) carbohydrate recognition domain at low pH. FEBS Journal, 2014, 281, 3739-3750. | 2.2 | 8 |
| 171 | Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology, 2014, 454-455, 197-205. | 1.1 | 149 |
| 172 | DC-SIGN, DC-SIGNR and LSECtin: C-Type Lectins for Infection. International Reviews of Immunology, 2014, 33, 54-66. | 1.5 | 55 |
| 173 | Distinct usage of three C-type lectins by Japanese encephalitis virus: DC-SIGN, DC-SIGNR, and LSECtin. Archives of Virology, 2014, 159, 2023-2031. | 0.9 | 34 |
| 174 | Influence of HLA gene polymorphisms on susceptibility and outcome post infection with the SARS-CoV virus. Virologica Sinica, 2014, 29, 128-130. | 1.2 | 22 |
| 175 | Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virology Journal, 2014, 11, 82. | 1.4 | 218 |
| 176 | The Pathology and Pathogenesis of Experimental Severe Acute Respiratory Syndrome and Influenza in Animal Models. Journal of Comparative Pathology, 2014, 151, 83-112. | 0.1 | 143 |
| 177 | Single amino acid substitution (G42E) in the receptor binding domain of mouse mammary tumour virus envelope protein facilitates infection of non-murine cells in a transferrin receptor 1-independent manner. Retrovirology, 2015, 12, 43. | 0.9 | 18 |
| 178 | The Roles of Direct Recognition by Animal Lectins in Antiviral Immunity and Viral Pathogenesis. Molecules, 2015, 20, 2272-2295. | 1.7 | 47 |
| 179 | Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. Virology, 2015, 479-480, 247-258. | 1.1 | 80 |
| 180 | The Evolution of HIV-1 Interactions with Coreceptors and Mannose C-Type Lectin Receptors. Progress in Molecular Biology and Translational Science, 2015, 129, 109-140. | 0.9 | 6 |
| 181 | Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1. Journal of Virology, 2015, 89, 8816-8827. | 1.5 | 46 |
| 182 | Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology. Journal of Virology, 2015, 89, 2995-3007. | 1.5 | 186 |
| 183 | SARS coronavirus infections of the lower respiratory tract and their prevention. , 2016, , 45-53. | | 1 |
| 184 | Endocytic function is critical for influenza A virus infection via DC-SIGN and L-SIGN. Scientific Reports, 2016, 6, 19428. | 1.6 | 44 |
| 185 | SARS-CoV fusion peptides induce membrane surface ordering and curvature. Scientific Reports, 2016, 6, 37131. | 1.6 | 55 |
| 186 | Identification of the Fusion Peptide-Containing Region in Betacoronavirus Spike Glycoproteins. Journal of Virology, 2016, 90, 5586-5600. | 1.5 | 65 |
| 187 | Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant. Methods in Molecular Biology, 2016, 1403, 269-284. | 0.4 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 188 | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus. Journal of Virology, 2016, 90, 9114-9127. | 1.5 | 68 |
| 189 | Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nature Structural and Molecular Biology, 2016, 23, 899-905. | 3.6 | 366 |
| 190 | DC-SIGN and L-SIGN Are Attachment Factors That Promote Infection of Target Cells by Human Metapneumovirus in the Presence or Absence of Cellular Glycosaminoglycans. Journal of Virology, 2016, 90, 7848-7863. | 1.5 | 9 |
| 191 | Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infectious Diseases, 2016, 2, 361-376. | 1.8 | 265 |
| 192 | Surface vimentin is critical for the cell entry of SARS-CoV. Journal of Biomedical Science, 2016, 23, 14. | 2.6 | 130 |
| 193 | Animal Models of Human Viral Diseases. , 2017, , 853-901. | | 8 |
| 194 | Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. Virology, 2018, 517, 3-8. | 1.1 | 251 |
| 195 | Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric Infections. Journal of Virology, 2018, 92, . | 1.5 | 124 |
| 196 | Identification and application of self-binding zipper-like sequences in SARS-CoV spike protein. International Journal of Biochemistry and Cell Biology, 2018, 101, 103-112. | 1.2 | 6 |
| 197 | The S2 Subunit of Infectious Bronchitis Virus Beaudette Is a Determinant of Cellular Tropism. Journal of Virology, 2018, 92, . | 1.5 | 47 |
| 198 | Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. Journal of Biological Chemistry, 2018, 293, 11709-11726. | 1.6 | 153 |
| 199 | Exploitation of glycosylation in enveloped virus pathobiology. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 1480-1497. | 1.1 | 383 |
| 200 | Membrane Composition Modulates Fusion by Altering Membrane Properties and Fusion Peptide Structure. Journal of Membrane Biology, 2019, 252, 261-272. | 1.0 | 47 |
| 201 | Membrane Cholesterol Modulates Oligomeric Status and Peptide-Membrane Interaction of Severe Acute Respiratory Syndrome Coronavirus Fusion Peptide. Journal of Physical Chemistry B, 2019, 123, 10654-10662. | 1.2 | 101 |
| 202 | From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses, 2019, 11, 59. | 1.5 | 919 |
| 203 | Gold nanoparticleâ€adjuvanted S protein induces a strong antigenâ€specific IgG response against severe acute respiratory syndromeâ€related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Microbiology and Immunology, 2020, 64, 33-51. | 0.7 | 140 |
| 204 | Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression. Antioxidants, 2020, 9, 936. | 2.2 | 104 |
| 205 | Assessing the SARS-CoV-2 threat to wildlife: Potential risk to a broad range of mammals. Perspectives in Ecology and Conservation, 2020, 18, 223-234. | 1.0 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 206 | From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infection, Genetics and Evolution, 2020, 85, 104502. | 1.0 | 178 |
| 207 | Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis. Clinical Microbiology Reviews, 2020, 34, . | 5.7 | 28 |
| 208 | Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2. European Journal of Pharmacology, 2020, 887, 173545. | 1.7 | 30 |
| 209 | Immune Modulatory Effects of Vitamin D on Viral Infections. Nutrients, 2020, 12, 2879. | 1.7 | 66 |
| 210 | Understand variability of COVID-19 through population and tissue variations in expression of SARS-CoV-2 host genes. Informatics in Medicine Unlocked, 2020, 21, 100443. | 1.9 | 24 |
| 211 | Mass Spectrometry Analysis of Newly Emerging Coronavirus HCoV-19 Spike Protein and Human ACE2 Reveals Camouflaging Glycans and Unique Post-Translational Modifications. Engineering, 2021, 7, 1441-1451. | 3.2 | 52 |
| 212 | Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll. Medical Hypotheses, 2020, 143, 110080. | 0.8 | 3 |
| 213 | COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges. Gastroenterology Research and Practice, 2020, 2020, 1-7. | 0.7 | 7 |
| 214 | Prominent Receptors of Liver Sinusoidal Endothelial Cells in Liver Homeostasis and Disease. Frontiers in Physiology, 2020, 11, 873. | 1.3 | 61 |
| 215 | Immune-mediated approaches against COVID-19. Nature Nanotechnology, 2020, 15, 630-645. | 15.6 | 260 |
| 216 | The role of host genetics in the immune response to SARSâ€CoVâ€2 and COVIDâ€19 susceptibility and severity. Immunological Reviews, 2020, 296, 205-219. | 2.8 | 175 |
| 217 | COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Cells, 2020, 9, 1652. | 1.8 | 210 |
| 218 | A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. International Journal of Biological Macromolecules, 2020, 164, 66-76. | 3.6 | 38 |
| 219 | A new threat from an old enemy: Reâ€'emergence of coronavirus (Review). International Journal of Molecular Medicine, 2020, 45, 1631-1643. | 1.8 | 175 |
| 220 | Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics. Future Medicinal Chemistry, 2020, 12, 1647-1656. | 1.1 | 49 |
| 221 | Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. Life Sciences, 2020, 257, 118102. | 2.0 | 248 |
| 222 | ACE2, the Receptor that Enables Infection by SARSâ€CoVâ€2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators. ChemMedChem, 2020, 15, 1682-1690. | 1.6 | 34 |
| 223 | Infectivity, virulence, pathogenicity, host-pathogen interactions of SARS and SARS-CoV-2 in experimental animals: a systematic review. Veterinary Research Communications, 2020, 44, 101-110. | 0.6 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 224 | Mining a GWAS of Severe Covid-19. New England Journal of Medicine, 2020, 383, 2588-2589. | 13.9 | 20 |
| 225 | JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy. Postgraduate Medicine, 2021, 133, 489-507. | 0.9 | 110 |
| 226 | Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations. International Journal of Legal Medicine, 2020, 134, 2209-2214. | 1.2 | 51 |
| 227 | Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country. Frontiers in Immunology, 2020, 11, 2008. | 2.2 | 23 |
| 228 | A comparative overview of COVID-19, MERS and SARS: Review article. International Journal of Surgery, 2020, 81, 1-8. | 1.1 | 81 |
| 229 | Coronaviruses and the central nervous system. Journal of NeuroVirology, 2020, 26, 459-473. | 1.0 | 43 |
| 230 | Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID19 patients. Emerging Microbes and Infections, 2020, 9, 1900-1911. | 3.0 | 57 |
| 231 | Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology. Advances in Experimental Medicine and Biology, 2020, 21, 13-127. | 0.8 | 29 |
| 232 | A 21st Century Evil: Immunopathology and New Therapies of COVID-19. Frontiers in Immunology, 2020, 11, 562264. | 2.2 | 8 |
| 233 | Exploring Host Genetic Polymorphisms Involved in SARS-CoV Infection Outcomes: Implications for Personalized Medicine in COVID-19. International Journal of Genomics, 2020, 2020, 1-8. | 0.8 | 19 |
| 234 | The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development. Frontiers in Immunology, 2020, 11, 1880. | 2.2 | 60 |
| 235 | â€œA Chain Only as Strong as Its Weakest Linkâ€: An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19. Journal of Proteome Research, 2020, 19, 4327-4338. | 1.8 | 33 |
| 236 | Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. Frontiers in Microbiology, 2020, 11, 1818. | 1.5 | 81 |
| 237 | Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. Neuroscientist, 2021, 27, 582-603. | 2.6 | 238 |
| 238 | No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19. Nanomedicine, 2020, 15, 2411-2427. | 1.7 | 19 |
| 239 | Dendritic Cells and SARS-CoV-2 Infection: Still an Unclarified Connection. Cells, 2020, 9, 2046. | 1.8 | 46 |
| 240 | A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment. Frontiers in Molecular Biosciences, 2020, 7, 186. | 1.6 | 24 |
| 241 | The Enigma of Endothelium in COVID-19. Frontiers in Physiology, 2020, 11, 989. | 1.3 | 70 |

| # | Article | IF | Citations |
|---|---|---|---|
| 242 | COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathogens, 2020, 16, e1008762. | 2.1 | 194 |
| 243 | A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nature Communications, 2020, 11, 4198. | 5.8 | 132 |
| 244 | Deciphering SARS-CoV-2 Virologic and Immunologic Features. International Journal of Molecular Sciences, 2020, 21, 5932. | 1.8 | 28 |
| 245 | COVID-19 and possible links with Parkinsonâ€™s disease and parkinsonism: from bench to bedside. Npj Parkinson's Disease, 2020, 6, 18. | 2.5 | 120 |
| 246 | Current Understanding, Knowledge Gaps and a Perspective on the Future of COVID-19 Infections: A Systematic Review. Indian Journal of Medical Microbiology, 2020, 38, 1-8. | 0.3 | 10 |
| 247 | Immunohistochemical Study of SARS-CoV-2 Viral Entry Factors in the Cornea and Ocular Surface. Cornea, 2020, 39, 1556-1562. | 0.9 | 54 |
| 248 | COVID-19: from an acute to chronic disease? Potential long-term health consequences. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 297-310. | 2.7 | 224 |
| 249 | The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature. American Journal of Human Genetics, 2020, 107, 381-402. | 2.6 | 51 |
| 250 | The immunology of SARS-CoV-2 infection, the potential antibody based treatments and vaccination strategies. Expert Review of Anti-Infective Therapy, 2020, 19, 1-12. | 2.0 | 10 |
| 251 | COVID-19;-The origin, genetics,and management of the infection of mothers and babies. Egyptian Journal of Basic and Applied Sciences, 2020, 7, 371-388. | 0.2 | 0 |
| 252 | Recent updates on COVID-19: A holistic review. Heliyon, 2020, 6, e05706. | 1.4 | 16 |
| 253 | COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. International Journal of Environmental Research and Public Health, 2020, 17, 8155. | 1.2 | 63 |
| 254 | SARS-CoV-2 mutations and where to find them: an <i>in silico</i> perspective of structural changes and antigenicity of the spike protein. Journal of Biomolecular Structure and Dynamics, 2022, 40, 3336-3346. | 2.0 | 1 |
| 255 | Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations. Archives of Dermatological Research, 2021, 313, 611-622. | 1.1 | 11 |
| 256 | Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view. Autoimmunity Reviews, 2020, 19, 102570. | 2.5 | 30 |
| 257 | Letter to the editor: Anti-RAS drugs and SARS-CoV-2 infection. Acta Pharmaceutica Sinica B, 2020, 10, 1251-1252. | 5.7 | 11 |
| 258 | Expression of the SARS-CoV-2 <i>ACE2</i> Receptor in the Human Airway Epithelium. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 219-229. | 2.5 | 208 |
| 259 | DC/Lâ€SIGNs of hope in the COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 1396-1398. | 2.5 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 260 | COVID-19, Angiotensin Receptor Blockers, and the Brain. Cellular and Molecular Neurobiology, 2020, 40, 667-674. | 1.7 | 30 |
| 261 | Focus on Receptors for Coronaviruses with Special Reference to Angiotensin- Converting Enzyme 2 as a Potential Drug Target - A Perspective. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 807-811. | 0.6 | 146 |
| 262 | From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. Microbes and Infection, 2020, 22, 245-253. | 1.0 | 36 |
| 263 | Infectivity of human coronavirus in the brain. EBioMedicine, 2020, 56, 102799. | 2.7 | 82 |
| 264 | The ocular surface, coronaviruses and COVIDâ€19. Australasian journal of optometry, The, 2020, 103, 418-424. | 0.6 | 75 |
| 265 | Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?. PLoS Pathogens, 2020, 16, e1008421. | 2.1 | 318 |
| 266 | Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2. Biological Procedures Online, 2020, 22, 11. | 1.4 | 32 |
| 267 | Attenuated Interferon and Proinflammatory Response in SARS-CoV-2â€"Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation. Journal of Infectious Diseases, 2020, 222, 734-745. | 1.9 | 165 |
| 268 | Corona virus versus existence of human on the earth: A computational and biophysical approach. International Journal of Biological Macromolecules, 2020, 161, 271-281. | 3.6 | 32 |
| 269 | Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thrombosis Research, 2020, 193, 110-115. | 0.8 | 121 |
| 270 | Rationale for targeting complement in COVIDâ€19. EMBO Molecular Medicine, 2020, 12, e12642. | 3.3 | 101 |
| 271 | Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis, 2020, 10, 102-108. | 2.4 | 1,208 |
| 272 | Cell-Mediated Immune Responses to COVID-19 Infection. Frontiers in Immunology, 2020, 11, 1662. | 2.2 | 48 |
| 273 | COVID-19 Sepsis and Microcirculation Dysfunction. Frontiers in Physiology, 2020, 11, 747. | 1.3 | 79 |
| 274 | Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Advances in Biological Regulation, 2020, 77, 100741. | 1.4 | 172 |
| 275 | SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virusâ€"Host Interaction. International Journal of Molecular Sciences, 2020, 21, 4549. | 1.8 | 69 |
| 276 | C-type Lectins in Immunity to Lung Pathogens. Current Topics in Microbiology and Immunology, 2020, 429, 19-62. | 0.7 | 2 |
| 277 | Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host and Microbe, 2020, 27, 325-328. | 5.1 | 1,860 |

| # | Article | IF | Citations |
|---|---|---|---|
| 278 | The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular Research, 2020, 116, 1097-1100. | 1.8 | 912 |
| 279 | COVIDâ€•19: Risk groups, mechanistic insights and challenges. International Journal of Clinical Practice, 2020, 74, e13512. | 0.8 | 21 |
| 280 | Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, 2020, 181, 905-913.e7. | 13.5 | 1,827 |
| 281 | COVID-19 pathophysiology: A review. Clinical Immunology, 2020, 215, 108427. | 1.4 | 1,414 |
| 282 | Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitorsâ€"lessons from available evidence and insights into COVID-19. Hypertension Research, 2020, 43, 648-654. | 1.5 | 330 |
| 283 | SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet, The, 2020, 395, 1517-1520. | 6.3 | 936 |
| 284 | Pathogenesis of COVID-19 from a cell biology perspective. European Respiratory Journal, 2020, 55, 2000607. | 3.1 | 618 |
| 285 | Human coronavirus spike protein-host receptor recognition. Progress in Biophysics and Molecular Biology, 2021, 161, 39-53. | 1.4 | 34 |
| 286 | Viral Infections of the Upper Airway in the Setting of COVID-19: A Primer for Rhinologists. American Journal of Rhinology and Allergy, 2021, 35, 122-131. | 1.0 | 5 |
| 287 | Advances in research on ACE2 as a receptor for 2019-nCoV. Cellular and Molecular Life Sciences, 2021, 78, 531-544. | 2.4 | 87 |
| 288 | What HIV in the Brain Can Teach Us About SARS-CoV-2 Neurological Complications?. AIDS Research and Human Retroviruses, 2021, 37, 255-265. | 0.5 | 15 |
| 289 | The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies. International Immunopharmacology, 2021, 92, 107051. | 1.7 | 33 |
| 290 | Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharmaceutica Sinica B, 2021, 11, 1-12. | 5.7 | 93 |
| 291 | SARS-CoV-2: Targeted managements and vaccine development. Cytokine and Growth Factor Reviews, 2021, 58, 16-29. | 3.2 | 44 |
| 292 | COVID-19 endocrinopathy with hindsight from SARS. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E139-E150. | 1.8 | 55 |
| 293 | Clinical characteristics of COVIDâ€•19 patients with hepatitis B virus infection â€" a retrospective study. Liver International, 2021, 41, 720-730. | 1.9 | 46 |
| 294 | Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019). Chemistry Africa, 2021, 4, 1-13. | 1.2 | 28 |
| 295 | Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection. Journal of Intensive Care Medicine, 2021, 36, 18-41. | 1.3 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 296 | Molecular diversity of coronavirus host cell entry receptors. FEMS Microbiology Reviews, 2021, 45, . | 3.9 | 75 |
| 297 | Immunological imprint of COVIDâ€19 on human peripheral blood leukocyte populations. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 751-765. | 2.7 | 71 |
| 298 | Tissue Distribution of ACE2 Protein in Syrian Golden Hamster (Mesocricetus auratus) and Its Possible Implications in SARS-CoV-2 Related Studies. Frontiers in Pharmacology, 2020, 11, 579330. | 1.6 | 30 |
| 299 | Hypercoagulability in COVID-19: A review of the potential mechanisms underlying clotting disorders. SAGE Open Medicine, 2021, 9, 205031212110029. | 0.7 | 18 |
| 300 | The Fatty Acid Lipid Metabolism Nexus in COVID-19. Viruses, 2021, 13, 90. | 1.5 | 56 |
| 301 | N- and O-Glycosylation of the SARS-CoV-2 Spike Protein. Analytical Chemistry, 2021, 93, 2003-2009. | 3.2 | 159 |
| 302 | Novel Targets of SARS-CoV-2 Spike Protein in Human Fetal Brain Development Suggest Early Pregnancy Vulnerability. Frontiers in Neuroscience, 2020, 14, 614680. | 1.4 | 15 |
| 303 | Spike glycoproteins: Their significance for corona viruses and receptor binding activities for pathogenesis and viral survival. Microbial Pathogenesis, 2021, 150, 104719. | 1.3 | 12 |
| 304 | Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?. International Journal of Molecular Sciences, 2021, 22, 992. | 1.8 | 106 |
| 305 | Oligomerization of Fusion Proteins: A Common Symptom for Class I Viruses. , 2021, , 693-712. | | 1 |
| 306 | Nucleocapsid and Spike Proteins of SARS-CoV-2 Drive Neutrophil Extracellular Trap Formation. Immune Network, 2021, 21, e16. | 1.6 | 21 |
| 307 | COVID-19: Molecular and Cellular Response. Frontiers in Cellular and Infection Microbiology, 2021, 11, 563085. | 1.8 | 31 |
| 308 | COVID-19: a new emerging respiratory disease from the neurological perspective. Environmental Science and Pollution Research, 2021, 28, 40445-40459. | 2.7 | 21 |
| 309 | SARSâ€“CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. Infectious Disease Reports, 2021, 13, 102-125. | 1.5 | 24 |
| 310 | COVID-19-associated liver injury: from bedside to bench. Journal of Gastroenterology, 2021, 56, 218-230. | 2.3 | 39 |
| 311 | SARS-CoV-2 and endothelial cell interaction in COVID-19: molecular perspectives. Vascular Biology (Bristol, England), 2021, 3, R15-R23. | 1.2 | 31 |
| 312 | Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. Frontiers in Immunology, 2021, 12, 640093. | 2.2 | 93 |
| 313 | Multi-organ proteomic landscape of COVID-19 autopsies. Cell, 2021, 184, 775-791.e14. | 13.5 | 272 |

| # | Article | IF | Citations |
|---|---|---|---|
| 314 | Molecular recognition in the infection, replication, and transmission of COVID-19-causing SARS-CoV-2: an emerging interface of infectious disease, biological chemistry, and nanoscience. NPG Asia Materials, 2021, 13, . | 3.8 | 15 |
| 315 | COVID-19: Immunology, Immunopathogenesis and Potential Therapies. International Reviews of Immunology, 2022, 41, 171-206. | 1.5 | 30 |
| 316 | Scouting the receptor-binding domain of SARSÂcoronavirusÂ2: aÂcomprehensive immunoinformatics inquisition. Future Virology, 2021, 16, 117-132. | 0.9 | 5 |
| 317 | Immunotherapeutic strategies to target vulnerabilities in the Ebolavirus glycoprotein. Immunity, 2021, 54, 412-436. | 6.6 | 23 |
| 318 | An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. Viruses, 2021, 13, 560. | 1.5 | 15 |
| 319 | Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial. Trials, 2021, 22, 199. | 0.7 | 14 |
| 320 | Precision therapeutic targets for COVID-19. Virology Journal, 2021, 18, 66. | 1.4 | 40 |
| 321 | Coronaviruses in humans and animals: the role of bats in viral evolution. Environmental Science and Pollution Research, 2021, 28, 19589-19600. | 2.7 | 40 |
| 322 | ACE2, TMPRSS2 and L-SIGN expression in placentae from HIV-positive pregnancies exposed to antiretroviral therapyâ€"implications for SARS-CoV-2 placental infection. Journal of Infectious Diseases, 2021, 224, S631-S641. | 1.9 | 2 |
| 323 | An Integrated Approach of the Potential Underlying Molecular Mechanistic Paradigms of SARS-CoV-2-Mediated Coagulopathy. Indian Journal of Clinical Biochemistry, 2021, 36, 387-403. | 0.9 | 5 |
| 324 | Coronavirus disease 2019 respiratory disease in children: clinical presentation and pathophysiology. Current Opinion in Pediatrics, 2021, 33, 302-310. | 1.0 | 2 |
| 325 | COVID-19 and Alzheimerâ€™s disease: how one crisis worsens the other. Translational Neurodegeneration, 2021, 10, 15. | 3.6 | 74 |
| 326 | Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nature Genetics, 2021, 53, 801-808. | 9.4 | 188 |
| 327 | Chikungunya and Zika Viruses: Co-Circulation and the Interplay between Viral Proteins and Host Factors. Pathogens, 2021, 10, 448. | 1.2 | 7 |
| 328 | Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury. Biomedicine and Pharmacotherapy, 2021, 136, 111193. | 2.5 | 42 |
| 329 | The Role of the SARS-CoV-2 S-Protein Glycosylation in the Interaction of SARS-CoV-2/ACE2 and Immunological Responses. Viral Immunology, 2021, 34, 165-173. | 0.6 | 36 |
| 330 | KanatlÄ± KoronaviruslarÄ±nÄ±n Zoonotik Potansiyelinin DeÄŸerlendirilmesi. Veteriner Farmakoloji Ve Toksikoloji DerneÄŸi BÃ¼lteni, 0, , . | 0.1 | 0 |
| 331 | Acute Kidney Injury in COVID-19: a Brief Review. Indian Journal of Surgery, 2021, 83, 398-402. | 0.2 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 332 | Human cell receptors: potential drug targets to combat COVID-19. Amino Acids, 2021, 53, 813-842. | 1.2 | 21 |
| 333 | Analysis of COVID-19 on Diagnosis, Vaccine, Treatment, and Pathogenesis with Clinical Scenarios. Clinics and Practice, 2021, 11, 309-321. | 0.6 | 6 |
| 334 | Structural insights on the interaction potential of natural leads against major protein targets of SARS-CoV-2: Molecular modelling, docking and dynamic simulation studies. Computers in Biology and Medicine, 2021, 132, 104325. | 3.9 | 18 |
| 335 | Complement Proteins as Soluble Pattern Recognition Receptors for Pathogenic Viruses. Viruses, 2021, 13, 824. | 1.5 | 12 |
| 336 | Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management. Heliyon, 2021, 7, e07068. | 1.4 | 27 |
| 337 | DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist. PLoS Pathogens, 2021, 17, e1009576. | 2.1 | 133 |
| 338 | COVID-19 and Hypertension: The What, the Why, and the How. Frontiers in Physiology, 2021, 12, 665064. | 1.3 | 44 |
| 339 | SARS-CoV-2: From the pathogenesis to potential anti-viral treatments. Biomedicine and Pharmacotherapy, 2021, 137, 111352. | 2.5 | 23 |
| 340 | Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infection, Genetics and Evolution, 2021, 90, 104773. | 1.0 | 72 |
| 341 | CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2. ACS Central Science, 2021, 7, 1156-1165. | 5.3 | 165 |
| 342 | Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. Frontiers in Pharmacology, 2021, 12, 575877. | 1.6 | 18 |
| 343 | Temporal evolution, most influential studies and sleeping beauties of the coronavirus literature. Scientometrics, 2021, 126, 7005-7050. | 1.6 | 12 |
| 344 | SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. Immunity, 2021, 54, 1304-1319.e9. | 6.6 | 115 |
| 345 | Nanotechnologyâ€Based Approach to Combat Pandemic COVID 19: A Review. Macromolecular Symposia, 2021, 397, 2000336. | 0.4 | 2 |
| 346 | Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. Drug Metabolism Reviews, 2021, 53, 508-541. | 1.5 | 0 |
| 347 | In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. BioMed Research International, 2021, 2021, 1-21. | 0.9 | 9 |
| 348 | Coronavirus and its terrifying inning around the globe: The pharmaceutical cares at the main frontline. Chemosphere, 2021, 275, 129968. | 4.2 | 7 |
| 349 | Host-Pathogen Adhesion as the Basis of Innovative Diagnostics for Emerging Pathogens. Diagnostics, 2021, 11, 1259. | 1.3 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 350 | Are Lactobacillus Bulgaricus and Bacillus Calmette-GuÃ©rin vaccine suitable for patient protection against SARS-CoV-2 infection?. Romanian Journal of Rhinology, 2021, 11, 101-110. | 0.1 | 0 |
| 351 | A bird's eye view on the role of dendritic cells in SARSâ€CoVâ€2 infection: Perspectives for immuneâ€based vaccines. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 100-110. | 2.7 | 25 |
| 352 | Expression of SARS-CoV-2 Entry Factors in Human Alveolar Type II Cells in Aging and Emphysema. Biomedicines, 2021, 9, 779. | 1.4 | 3 |
| 353 | Possible Link between SARS-CoV-2 Infection and Parkinsonâ€™s Disease: The Role of Toll-Like Receptor 4. International Journal of Molecular Sciences, 2021, 22, 7135. | 1.8 | 23 |
| 354 | L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus. JCI Insight, 2021, 6, . | 2.3 | 31 |
| 355 | Future antiviral polymers by plasma processing. Progress in Polymer Science, 2021, 118, 101410. | 11.8 | 31 |
| 356 | Phytocompounds of Rheum emodi, Thymus serpyllum, and Artemisia annua Inhibit Spike Protein of SARS-CoV-2 Binding to ACE2 Receptor: In Silico Approach. Current Pharmacology Reports, 2021, 7, 135-149. | 1.5 | 50 |
| 357 | COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. Biomedicines, 2021, 9, 903. | 1.4 | 5 |
| 359 | Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19). Frontiers in Medicine, 2021, 8, 702066. | 1.2 | 14 |
| 360 | Virology, Molecular Pathogenesis and Diagnosis of SARS-CoV-2: A Systematic Review. Shanghai Ligong Daxue Xuebao/Journal of University of Shanghai for Science and Technology, 2021, 23, 352-365. | 0.1 | 1 |
| 361 | Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains. MBio, 2021, 12, e0159021. | 1.8 | 49 |
| 362 | Comprehensive Analysis of SARS-COV-2 Drug Targets and Pharmacological Aspects in Treating the COVID-19. Current Molecular Pharmacology, 2022, 15, 393-417. | 0.7 | 6 |
| 363 | SARS-CoV-2 Impairs Dendritic Cells and Regulates DC-SIGN Gene Expression in Tissues. International Journal of Molecular Sciences, 2021, 22, 9228. | 1.8 | 15 |
| 364 | A Combination of Î±-Lipoic Acid (ALA) and Palmitoylethanolamide (PEA) Blocks Endotoxin-Induced Oxidative Stress and Cytokine Storm: A Possible Intervention for COVID-19. Journal of Dietary Supplements, 2023, 20, 133-155. | 1.4 | 14 |
| 365 | SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection. Glycoconjugate Journal, 2021, 38, 611-623. | 1.4 | 17 |
| 366 | Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 Replication by Hypertonic Saline Solution in Lung and Kidney Epithelial Cells. ACS Pharmacology and Translational Science, 2021, 4, 1514-1527. | 2.5 | 17 |
| 367 | A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems. Vaccines, 2021, 9, 1086. | 2.1 | 19 |
| 368 | Severe Acute Respiratory Syndrome Coronavirus 2: The Role of the Main Components of the Innate Immune System. Inflammation, 2021, 44, 2151-2169. | 1.7 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 369 | Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101752. | 0.7 | 12 |
| 370 | COVID-19: Pathogenesis and Pharmacological Basis for Use of Passive Antibody Therapy. Current Drug Therapy, 2021, 15, 448-456. | 0.2 | 1 |
| 371 | A review on clinical, pathological characteristics and drug designing for COVID-19. Arab Journal of Basic and Applied Sciences, 2021, 28, 172-186. | 1.0 | 1 |
| 372 | No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. Scientific Reports, 2021, 11, 413. | 1.6 | 156 |
| 373 | Genomic Evidence Provides the Understanding of SARS-CoV-2 Composition, Divergence, and Diagnosis. , 2021, , 63-79. | | 0 |
| 375 | Insights from the Association of SARS-CoV S-Protein with its Receptor, ACE2. Advances in Experimental Medicine and Biology, 2006, 581, 209-218. | 0.8 | 20 |
| 376 | Attachment Factor and Receptor Engagement of Sars Coronavirus and Human Coronavirus NL63. Advances in Experimental Medicine and Biology, 2006, 581, 219-227. | 0.8 | 8 |
| 377 | Proteolysis of Sars-Associated Coronavirus Spike Glycoprotein. Advances in Experimental Medicine and Biology, 2006, 581, 235-240. | 0.8 | 12 |
| 378 | Increased Viral Titers and Subtle Changes in Plaque Morphology Upon Passage of SARS-CoV in Cells from Different Species. Advances in Experimental Medicine and Biology, 2006, 581, 259-263. | 0.8 | 3 |
| 379 | Human Coronavirus 229E can Use CD209L (L-Sign) to Enter Cells. Advances in Experimental Medicine and Biology, 2006, 581, 265-269. | 0.8 | 32 |
| 380 | Analysis of SARS-CoV Receptor Activity of ACE2 Orthologs. Advances in Experimental Medicine and Biology, 2006, 581, 277-280. | 0.8 | 5 |
| 381 | RAT Coronavirus Infection of Primary RAT Alveolar Epithelial Cells. Advances in Experimental Medicine and Biology, 2006, 581, 351-356. | 0.8 | 6 |
| 382 | Infection of Human Airway Epithelia by Sars Coronavirus is Associated with ACE2 Expression and Localization. Advances in Experimental Medicine and Biology, 2006, 581, 479-484. | 0.8 | 27 |
| 383 | Coronaviruses. , 2014, , 199-223. | | 18 |
| 384 | The C Type Lectins DC-SIGN and L-SIGN. Methods in Molecular Biology, 2007, 379, 51-68. | 0.4 | 47 |
| 385 | Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics. , 2020, , 1-120. | | 3 |
| 386 | Molecular Biology of the SARS-Coronavirus. , 2010, , . | | 22 |
| 387 | Cellular Entry of the SARS Coronavirus: Implications for Transmission, Pathogenicity and Antiviral Strategies. , 2010, , 3-22. | | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 388 | SARS Coronavirus Pathogenesis and Therapeutic Treatment Design. , 2010, , 195-230. | | 1 |
| 389 | Host Immune Responses to SARS Coronavirus in Humans. , 2010, , 259-278. | | 15 |
| 390 | Attachment of human immunodeficiency virus to cells and its inhibition. , 2007, , 31-47. | | 4 |
| 391 | An Overview of the Crystallized Structures of the SARS-CoV-2. Protein Journal, 2020, 39, 600-618. | 0.7 | 32 |
| 392 | Î±-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19. Biochemical Society Transactions, 2020, 48, 1287-1295. | 1.6 | 48 |
| 393 | Antigenic modules in the N-terminal S1 region of the transmissible gastroenteritis virus spike protein. Journal of General Virology, 2011, 92, 1117-1126. | 1.3 | 18 |
| 394 | Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells. Journal of General Virology, 2006, 87, 1953-1960. | 1.3 | 111 |
| 410 | Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage. Clinical and Experimental Immunology, 2020, 202, 193-209. | 1.1 | 83 |
| 411 | Developments in the Search for Small-Molecule Inhibitors for Treatment of Severe Acute Respiratory Syndrome Coronavirus. , 0, , 209-222. | | 1 |
| 412 | Vaccines for Severe Acute Respiratory Syndrome Virus and Other Coronaviruses. , 0, , 379-407. | | 3 |
| 413 | Role of the Spike Glycoprotein of Human Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Virus Entry and Syncytia Formation. PLoS ONE, 2013, 8, e76469. | 1.1 | 210 |
| 417 | Options for COVID-19 Entry into Pulmonary Cells. Biomedical Journal of Scientific & Technical Research, 2020, 29, 22337-22338. | 0.0 | 1 |
| 418 | Pathomorphology of a new coronavirus infection COVID-19. Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2020, 35, 47-52. | 0.1 | 6 |
| 419 | COVID-19: Targeting the cytokine storm via cholinergic anti-inflammatory (Pyridostigmine). International Journal of Clinical Virology, 2020, 4, 041-046. | 0.1 | 5 |
| 420 | A Review of Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Iranian Journal of Medical Microbiology, 2020, 14, 154-161. | 0.1 | 5 |
| 421 | SARS Vaccine Development. Emerging Infectious Diseases, 2005, 11, 1016-1020. | 2.0 | 174 |
| 422 | C-type Lectin CD209L/L-SIGN and CD209/DC-SIGN: Cell Adhesion Molecules Turned to Pathogen Recognition Receptors. Biology, 2021, 10, 1. | 1.3 | 81 |
| 423 | Receptor-binding domain of SARS-Cov spike protein: Soluble expression in<i>E.coli</i>, purification and functional characterization. World Journal of Gastroenterology, 2005, 11, 6159. | 1.4 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 425 | Approaches towards fighting the COVIDâ€'19 pandemic (Review). International Journal of Molecular Medicine, 2020, 47, 3-22. | 1.8 | 48 |
| 426 | Decreased Proliferation of Mesenchymal Stem Cells in Corticosteroid-induced Osteonecrosis of Femoral Head. Orthopedics, 2008, 31, 444. | 0.5 | 45 |
| 427 | Decreased Proliferation of Mesenchymal Stem Cells in Corticosteroid-Induced Osteonecrosis of Femoral Head. Orthopedics, 2008, 31, . | 0.5 | 1 |
| 428 | Drug for corona virus: A systematic review. Indian Journal of Pharmacology, 2020, 52, 56. | 0.4 | 402 |
| 429 | SARS-CoV-2: A Piece of Bad News. Medeniyet Medical Journal, 2020, 35, 151-160. | 0.4 | 4 |
| 430 | Virology of SARS-CoV-2 and management of nCOVID-19 utilizing Immunomodulation properties of human mesenchymal stem cellsâ€"a literature review. Stem Cell Investigation, 2021, 8, 0-0. | 1.3 | 1 |
| 431 | Cell Entry of Animal Coronaviruses. Viruses, 2021, 13, 1977. | 1.5 | 12 |
| 432 | The effect of N-glycosylation of SARS-CoV-2 spike protein on the virus interaction with the host cell ACE2 receptor. IScience, 2021, 24, 103272. | 1.9 | 20 |
| 433 | Mechanisms of SARS-CoV-2 entry into cells. Nature Reviews Molecular Cell Biology, 2022, 23, 3-20. | 16.1 | 1,532 |
| 434 | CD13. The AFCS-nature Molecule Pages, 0, , . | 0.2 | 0 |
| 435 | Evaluation of current strategies to inhibit HIV entry, integration and maturation. , 2006, , 213-254. | | 0 |
| 438 | DC-SIGN Family of Receptors. , 2012, , 773-798. | | 5 |
| 439 | The Mycobacteria: a Postgenomic View. , 0, , 49-89. | | 0 |
| 440 | Emerging Nidovirus Infections. , 0, , 409-418. | | 1 |
| 441 | Severe Acute Respiratory Syndrome: Epidemiology, Pathogenesis, and Animal Models. , 0, , 299-311. | | 0 |
| 442 | Severe Acute Respiratory Syndrome (SARS). , 0, , 23-50. | | 1 |
| 446 | Perspective of molecular immune response of SARS-COV-2 infection. Jurnal Teknologi Laboratorium, 2020, 9, 58-66. | 0.4 | 4 |
| 448 | A Review of Human Coronavirusesâ€™ Receptors: The Host-Cell Targets for the Crown Bearing Viruses. Molecules, 2021, 26, 6455. | 1.7 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 450 | Identifying epitopes for cluster of differentiation and design of new peptides inhibitors against human SARS-CoV-2 spike RBD by an in-silico approach. Heliyon, 2020, 6, e05739. | 1.4 | 6 |
| 452 | <b>COVID-19: A Devastating Pandemic</b>. Pharmaceutical Sciences, 2020, 26, S3-S11. | 0.1 | 4 |
| 453 | Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. Cell Research, 2022, 32, 24-37. | 5.7 | 98 |
| 454 | COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting EnzymeÂ2, Mutual Effects and Pharmacotherapy. Frontiers in Endocrinology, 2021, 12, 772865. | 1.5 | 15 |
| 455 | Epigenetic glycosylation of SARS-CoV-2 impact viral infection through DC&L-SIGN receptors. IScience, 2021, 24, 103426. | 1.9 | 8 |
| 456 | Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection (Russian translation). Juvenis Scientia, 2021, 7, 28-59. | 0.1 | 1 |
| 457 | Lung epithelial cells interact with immune cells and bacteria to shape the microenvironment in tuberculosis. Thorax, 2022, 77, 408-416. | 2.7 | 23 |
| 458 | Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: A systematic review. Analytical Biochemistry, 2022, 640, 114546. | 1.1 | 19 |
| 459 | Pathologic basis of coronavirus disease 2019 (COVID-19) â€" An overview of cellular affinities, pathogenesis, clinical manifestations, autopsy findings and sequelae. Annals of Cytology and Pathology, 2020, , 078-083. | 0.3 | 1 |
| 460 | Pulmonary pathology of COVID-19. Journal of Lung, Pulmonary & Respiratory Research, 2020, 7, 79-83. | 0.3 | 0 |
| 461 | An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. RSC Medicinal Chemistry, 2022, 13, 647-675. | 1.7 | 3 |
| 462 | An Updated Review on the Role of Single Nucleotide Polymorphisms in COVID-19 Disease Severity: A Global Aspect. Current Pharmaceutical Biotechnology, 2022, 23, 1596-1611. | 0.9 | 2 |
| 464 | Immune Profiling of COVID-19 in Correlation with SARS and MERS. Viruses, 2022, 14, 164. | 1.5 | 11 |
| 465 | COVIDâ€•19 immunopathology with emphasis on Th17 response and cellâ€•based immunomodulation therapy: Potential targets and challenges. Scandinavian Journal of Immunology, 2022, 95, e13131. | 1.3 | 19 |
| 466 | Strategies for fighting pandemic virus infections: Integration of virology and drug delivery. Journal of Controlled Release, 2022, 343, 361-378. | 4.8 | 11 |
| 467 | Proteomic profiling identifies novel proteins for genetic risk of severe COVID-19: the Atherosclerosis Risk in Communities Study. Human Molecular Genetics, 2022, 31, 2452-2461. | 1.4 | 8 |
| 468 | SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19. International Journal of Molecular Sciences, 2022, 23, 1716. | 1.8 | 107 |
| 469 | Immunopathogenecity in COVID-19. , 2022, 8, 3-13. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 470 | Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review. Viruses, 2022, 14, 351. | 1.5 | 11 |
| 471 | COVID-19, liver dysfunction and pathophysiology: A conceptual discussion. World Journal of Gastroenterology, 2022, 28, 683-688. | 1.4 | 3 |
| 472 | Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry. Frontiers in Immunology, 2021, 12, 796855. | 2.2 | 63 |
| 474 | COVIDâ€•19: A systematic review and update on prevention, diagnosis, and treatment. MedComm, 2022, 3, e115. | 3.1 | 30 |
| 475 | COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities. Current Problems in Cardiology, 2022, , 101186. | 1.1 | 7 |
| 476 | Mild COVID-19 imprints a long-term inflammatory eicosanoid- and chemokine memory in monocyte-derived macrophages. Mucosal Immunology, 2022, 15, 515-524. | 2.7 | 37 |
| 478 | Thymoquinoneâ€™s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge. Frontiers in Pharmacology, 2022, 13, 848676. | 1.6 | 6 |
| 479 | Hypothetical Immunological and Immunogenetic Model of Heterogenous Effects of BCG Vaccination in SARS-CoV-2 Infections: BCG-induced Trained and Heterologous Immunity. Journal of Medical Science, 0, , e551. | 0.2 | 2 |
| 480 | Coronavirus Entry Inhibitors. Advances in Experimental Medicine and Biology, 2022, 1366, 101-121. | 0.8 | 3 |
| 481 | SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers. International Journal of Hematology-Oncology and Stem Cell Research, 0, , . | 0.3 | 4 |
| 486 | Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs, 2022, 36, 231-323. | 2.2 | 24 |
| 487 | Mechanisms of Immune Dysregulation in COVID-19 Are Different From SARS and MERS: A Perspective in Context of Kawasaki Disease and MIS-C. Frontiers in Pediatrics, 2022, 10, . | 0.9 | 6 |
| 488 | Severe Acute Respiratory Syndrome Coronavirus Entry as a Target of Antiviral Therapies. Antiviral Therapy, 2007, 12, 639-650. | 0.6 | 17 |
| 489 | Endotheliitis, shunts, and Ventilationâ€“Perfusion mismatch in coronavirus disease 2019: A literature review of disease mechanisms. Annals of Medicine and Surgery, 2022, , 103820. | 0.5 | 2 |
| 491 | Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2. Frontiers in Genetics, 0, 13, . | 1.1 | 1 |
| 492 | Mechanisms of COVID-19 pathogenesis in diabetes. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H403-H420. | 1.5 | 26 |
| 493 | Kathryn V. Holmes: A Career of Contributions to the Coronavirus Field. Viruses, 2022, 14, 1573. | 1.5 | 0 |
| 494 | Comprehensive overview of COVID-19-related respiratory failure: focus on cellular interactions. Cellular and Molecular Biology Letters, 2022, 27, . | 2.7 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 495 | Long-Term Health Consequences of SARS-CoV-2: Assumptions Based on SARS-CoV-1 and MERS-CoV Infections. Diagnostics, 2022, 12, 1852. | 1.3 | 2 |
| 496 | An evaluation of the 2019 novel coronavirus (COVID-19) disease. Current Trends in Pharmacy and Pharmaceutical Chemistry, 2022, 4, 90-97. | 0.1 | 0 |
| 497 | Role of aging in Bloodâ€"Brain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19. Fluids and Barriers of the CNS, 2022, 19, . | 2.4 | 10 |
| 498 | Iâ€™ve looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections. Frontiers in Immunology, 0, 13, . | 2.2 | 3 |
| 499 | CoVM2: Molecular Biological Data Integration of SARS-CoV-2 Proteins in a Macro-to-Micro Method. Biomolecules, 2022, 12, 1067. | 1.8 | 1 |
| 500 | Multivalent ACE2 engineeringâ€"A promising pathway for advanced coronavirus nanomedicine development. Nano Today, 2022, 46, 101580. | 6.2 | 7 |
| 501 | Research progress on etiology and pathogenesis of MERS-CoV and SARS-CoV. AIP Conference Proceedings, 2022, , . | 0.3 | 0 |
| 502 | Covid-19, nervous system pathology, and Parkinson's disease: Bench to bedside. International Review of Neurobiology, 2022, , 17-34. | 0.9 | 7 |
| 503 | The multifaceted roles of NLRP3-modulating proteins in virus infection. Frontiers in Immunology, 0, 13, . | 2.2 | 10 |
| 504 | Murine Hepatitis Virus, a Biosafety Level 2 Model for SARS-CoV-2, Can Remain Viable on Meat and Meat Packaging Materials for at Least 48 Hours. Microbiology Spectrum, 2022, 10, . | 1.2 | 3 |
| 505 | Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. Exploration of Immunology, 2022, 2, 648-664. | 1.7 | 1 |
| 506 | Immunology to Immunotherapeutics of SARS-CoV-2: Identification of Immunogenic Epitopes for Vaccine Development. Current Microbiology, 2022, 79, . | 1.0 | 3 |
| 507 | Current therapeutic strategies and possible effective drug delivery strategies against COVID-19. Current Drug Delivery, 2022, 19, . | 0.8 | 1 |
| 508 | Exploring the Targets of Novel Corona Virus and Docking-based Screening of Potential Natural Inhibitors to Combat COVID-19. Current Topics in Medicinal Chemistry, 2022, 22, 2410-2434. | 1.0 | 3 |
| 509 | CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. PLoS Pathogens, 2022, 18, e1010479. | 2.1 | 15 |
| 510 | Severe acute respiratory syndrome (SARS). , 2023, , 53-124. | | 0 |
| 511 | Vascular dysfunction in COVID-19 patients: update on SARS-CoV-2 infection of endothelial cells and the role of long non-coding RNAs. Clinical Science, 2022, 136, 1571-1590. | 1.8 | 7 |
| 512 | Immunosenescence and ACE2 protein expression: Association with SARS-CoV-2 in older adults. Open Journal of Asthma, 2022, 6, 008-017. | 2.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 513 | COVID-19 and pulmonary manifestations. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2022, 181, . | 0.0 | 0 |
| 514 | Severe COVID-19 May Impact Hepatic Fibrosis /Hepatic Stellate Cells Activation as Indicated by a Pathway and Population Genetic Study. Genes, 2023, 14, 22. | 1.0 | 3 |
| 515 | Innate immune recognition against SARS-CoV-2. Inflammation and Regeneration, 2023, 43, . | 1.5 | 8 |
| 517 | Comprehensive analysis of SARSâ€CoVâ€2 receptor proteins in human respiratory tissues identifies alveolar macrophages as potential virus entry site. Histopathology, 2023, 82, 846-859. | 1.6 | 0 |
| 518 | Membrane cholesterol regulates the oligomerization and fusogenicity of SARS-CoV fusion peptide: implications in viral entry. Physical Chemistry Chemical Physics, 2023, 25, 7815-7824. | 1.3 | 6 |
| 519 | Potent NKT cell ligands overcome SARS-CoV-2 immune evasion to mitigate viral pathogenesis in mouse models. PLoS Pathogens, 2023, 19, e1011240. | 2.1 | 6 |
| 520 | Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?. International Journal of Molecular Sciences, 2023, 24, 6253. | 1.8 | 3 |
| 521 | SARS-CoV-2 Receptors and Their Involvement in Cell Infection. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2023, 17, 1-11. | 0.3 | 0 |
| 522 | COVIDâ€19 and preeclampsia: The unique and the mutually nonexclusive clinical manifestations. American Journal of Reproductive Immunology, 2023, 89, . | 1.2 | 2 |
| 523 | Effect of coronaviruses on blood vessel permeability: potential therapeutic targets. Therapeutic Advances in Respiratory Disease, 2023, 17, 175346662311622. | 1.0 | 0 |
| 534 | Coronaviruses: The Common Cold, SARS, and MERS. , 2024, , 1-53. | | 0 |
| 536 | Panendothelitis Due to the SARS COV 2 Infection: Consequences on Hypertension and Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2023, , 181-227. | 0.1 | 0 |